Blocknomi
Key Takeaways Zymeworks has entered into an agreement to purchase Theravance Biopharma in an all-cash transaction valued at $929 million at $17 per share Acquisition pricing represents a 3.6% decrease…
Related articles
-
SpaceX (SPCX) Stock Climbs as SpaceXAI-Cursor Joint AI Model Launch Approaches
Blocknomi Published 08.07.2026 16:57
-
Micron (MU) Stock Slides as SK Hynix Launches U.S. Trading — Should Investors Buy the Dip?
Blocknomi Published 10.07.2026 12:35
-
Bitcoin clings to key support level as weekly US spot ETF outflows hit $1.8B and Fed rate hike bets mount: analysts
The Block Published 29.06.2026 12:00
-
ETH at $1,730: Down 65% With Its Biggest Upgrade Weeks Away
BeInCrypto Published 08.07.2026 15:02
-
Bernstein predicts acquisition wave as prediction markets consolidate
Crypto.News Published 29.06.2026 18:10
-
PhotonPay’s Instant B2B Transfers Chip Away at Crypto’s Settlement Advantage
BlockchainReporter Published 01.07.2026 08:30
-
Mega-Deals Drive Global M&A to $2.8 Trillion in First Half of 2026
BeInCrypto Published 01.07.2026 12:02
-
Galaxy turns Helios Bitcoin mine into AI hub for CoreWeave
Crypto.News Published 07.07.2026 10:16